GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Parlevliet, Edwin T ^a   Wang, Yanan ^a   Geerling, Janine J ^a   Schröder Van der Elst, Janny P ^a   Picha, Kristen ^b   O'Neil, Karyn ^b   Stojanovic Susulic, Vedrana ^b   Ort, Tatiana ^b   Havekes, Louis M ^a,c   Romijn, Johannes A ^a   Pijl, Hanno ^a   Rensen, Patrick C N ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E3; CNTO 3649; DIACYLGLYCEROL ACYLTRANSFERASE 1; EXENDIN 4; FATTY ACID SYNTHASE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOB GENE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIACYLGLYCEROL ACYLTRANSFERASE 1 GENE; DISEASE ASSOCIATION; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG MEGADOSE; FA SYNTHASE GENE; FATTY ACID OXIDATION; FATTY LIVER; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; INSULIN BLOOD LEVEL; LIPOGENESIS; LIPOLYSIS; LIVER METABOLISM; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C GENE; THERMOGENESIS;

ANIMALS; APOLIPOPROTEIN E3; APOLIPOPROTEINS B; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FATTY LIVER; GLUCAGON-LIKE PEPTIDE 1; INSULIN; LIPOGENESIS; LIVER; MALE; MICE; MICE, TRANSGENIC; PEPTIDES; RECEPTORS, GLUCAGON; VENOMS;

MUS; MUS MUSCULUS;

EID: 84868307468     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049152     Document Type: Article

References (45)

1. Stumvoll M, Goldstein BJ, van Haeften TW, (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365: 1333-1346.
2. Kahn SE, Hull RL, Utzschneider KM, (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444: 840-846.
3. Lewis JR, Mohanty SR, (2010) Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 55: 560-578.
4. Kreymann B, Williams G, Ghatei MA, Bloom SR, (1987) Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2: 1300-1304.
5. Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C, (1997) Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 77: 257-270.
6. Holst JJ, Orskov C, Nielsen OV, Schwartz TW, (1987) Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 211: 169-174.
7. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, et al. (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69-72.
8. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, et al. (1993) Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38: 665-673.
9. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, et al. (1996) Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81: 327-332.
10. Baggio LL, Drucker DJ, (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131-2157.
11. Exenatide (Byetta) for type 2 diabetes. Med Lett Drugs Ther 47: 45-46.
12. Parlevliet ET, Schroder-van der Elst JP, Corssmit EP, Picha K, O'Neil K, et al. (2009) CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice. J Pharmacol Exp Ther 328: 240-248.
13. Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, et al. (2007) Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 13: 444-450.
14. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, et al. (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24: 275-286.
15. van Vlijmen BJ, van den Maagdenberg AM, Gijbels MJ, van der Boom H, HogenEsch H, et al. (1994) Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest 93: 1403-1410.
16. van den Maagdenberg AM, Hofker MH, Krimpenfort PJ, de B, I, van VB, et al. (1993) Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem 268: 10540-10545.
17. Picha KM, Cunningham MR, Drucker DJ, Mathur A, Ort T, et al. (2008) Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis. Diabetes 57: 1926-1934.
18. Aalto-Setala K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, et al. (1992) Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest 90: 1889-1900.
19. Redgrave TG, Roberts DC, West CE, (1975) Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem 65: 42-49.
20. Li X, Catalina F, Grundy SM, Patel S, (1996) Method to measure apolipoprotein B-48 and B-100 secretion rates in an individual mouse: evidence for a very rapid turnover of VLDL and preferential removal of B-48- relative to B-100-containing lipoproteins. J Lipid Res 37: 210-220.
21. Bligh EG, Dyer WJ, (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917.
22. Mulvihill EE, Allister EM, Sutherland BG, Telford DE, Sawyez CG, et al. (2009) Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance. Diabetes 58: 2198-2210.
23. Gedulin BR, Smith P, Prickett KS, Tryon M, Barnhill S, et al. (2005) Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia 48: 1380-1385.
24. Green BD, Lavery KS, Irwin N, O'harte FP, Harriott P, et al. (2006) Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. J Pharmacol Exp Ther 318: 914-921.
25. Zander M, Madsbad S, Madsen JL, Holst JJ, (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359: 824-830.
26. Adiels M, Olofsson SO, Taskinen MR, Boren J, (2006) Diabetic dyslipidaemia. Curr Opin Lipidol 17: 238-246.
27. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA, (2006) Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43: 173-181.
28. Diraison F, Moulin P, Beylot M, (2003) Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab 29: 478-485.
29. Hellerstein MK, Neese RA, Schwarz JM, (1993) Model for measuring absolute rates of hepatic de novo lipogenesis and reesterification of free fatty acids. Am J Physiol 265: E814-E820.
30. Ferre P, Foretz M, Azzout-Marniche D, Becard D, Foufelle F, (2001) Sterol-regulatory-element-binding protein 1c mediates insulin action on hepatic gene expression. Biochem Soc Trans 29: 547-552.
31. Lin J, Yang R, Tarr PT, Wu PH, Handschin C, et al. (2005) Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP. Cell 120: 261-273.
32. Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, et al. (2010) Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51: 1584-1592.
33. Svegliati-Baroni G, Saccomanno S, Rychlicki C, Agostinelli L, De MS, et al. (2011) Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 31: 1285-1297.
34. Tomas E, Stanojevic V, Habener JF, (2010) GLP-1 (9-36) amide metabolite suppression of glucose production in isolated mouse hepatocytes. Horm Metab Res 42: 657-662.
35. Hsieh J, Longuet C, Baker CL, Qin B, Federico LM, et al. (2010) The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 53: 552-561.
36. Matikainen N, Manttari S, Schweizer A, Ulvestad A, Mills D, et al. (2006) Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 49: 2049-2057.
37. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, et al. (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115: 1343-1351.
38. Barrows BR, Parks EJ, (2006) Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states. J Clin Endocrinol Metab 91: 1446-1452.
39. Kastin AJ, Akerstrom V, Pan W, (2002) Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 18: 7-14.
40. Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP, (1995) Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 7: 2294-2300.
41. Parlevliet ET, de Leeuw van Weenen JE, Romijn JA, Pijl H, (2010) GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet. Am J Physiol Endocrinol Metab 299: E318-E324.
42. Nogueiras R, Perez-Tilve D, Veyrat-Durebex C, Morgan DA, Varela L, et al. (2009) Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J Neurosci 29: 5916-5925.
43. Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, et al. (2011) Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring) 19: 2310-2315.
44. Garber AJ, (2011) Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care 34Suppl 2: S279-S284.
45. Tahrani AA, Bailey CJ, Del PS, Barnett AH, (2011) Management of type 2 diabetes: new and future developments in treatment. Lancet 378: 182-197.